Study of advanced therapies for Crohn's or ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn's or ulcerative colitis for at least 3 months.
- Your disease is moderately to severely active.
- You've tried at least one standard treatment that didn't work well enough.
- You haven't had certain bowel surgeries recently or in the past (if Crohn's, no more than 3 bowel surgeries; no removal of more than 100 cm of small bowel; if colitis, no total colon removal).
- You are not allergic to certain medications called IL-23 inhibitors (like risankizumab) and haven't taken an experimental drug in the last month.
- You haven't taken certain advanced therapies (biologics or small molecule drugs) too recently before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests new therapies for people with a severe UC flare that hasn't improved after 5 days of high-dose steroids. It aims to find more effective options to control symptoms and avoid hospitalization.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.